MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are ...

Abstract: Compared with three-level inverters, four-level inverters need more switching times to balance the dc-link capacitor voltages, lowering the efficiency. This article proposes a four-level ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) ...

Neuroplasticity is the brain's ability to reorganize its structure, functions, and connections in response to experience, injury, or disease. It allows the brain to change and adapt, for example, by ...

Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead ...

Kyocera Corporation (President: Hideo Tanimoto; “Kyocera”)(TOKYO: 6971) announced that it has developed a new meta-lens that ...

Long-range couplings between lattice sites algorithmically speed up the efficiency of quantum walks. Scientists in China ...

Corcept Therapeutics (CORT) leverages Korlym’s commercial success in hypercortisolism, generating $559.3M in nine-month 2025 ...

A device smaller than a grain of dust is emerging as a surprisingly powerful candidate to reshape how quantum computers are ...